Pulmatrix, Inc. (NASDAQ:PULM – Get Rating) saw a significant drop in short interest in the month of April. As of April 30th, there was short interest totalling 27,700 shares, a drop of 74.4% from the April 15th total of 108,000 shares. Currently, 0.8% of the shares of the stock are sold short. Based on an average daily volume of 47,700 shares, the short-interest ratio is presently 0.6 days.
Several analysts have commented on PULM shares. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective (up from $5.00) on shares of Pulmatrix in a report on Wednesday, March 30th. StockNews.com started coverage on Pulmatrix in a report on Thursday, May 5th. They issued a “hold” rating on the stock. Finally, Zacks Investment Research lowered Pulmatrix from a “buy” rating to a “hold” rating in a report on Thursday, January 13th.
Large investors have recently modified their holdings of the company. Citadel Advisors LLC acquired a new stake in shares of Pulmatrix in the third quarter worth approximately $34,000. First Republic Investment Management Inc. lifted its position in Pulmatrix by 400.0% during the third quarter. First Republic Investment Management Inc. now owns 50,000 shares of the biotechnology company’s stock worth $40,000 after buying an additional 40,000 shares in the last quarter. Parallax Volatility Advisers L.P. purchased a new position in Pulmatrix during the fourth quarter worth approximately $43,000. Murchinson Ltd. purchased a new position in Pulmatrix during the fourth quarter worth approximately $44,000. Finally, Virtu Financial LLC purchased a new position in Pulmatrix during the fourth quarter worth approximately $58,000.
Pulmatrix (NASDAQ:PULM – Get Rating) last issued its quarterly earnings results on Tuesday, March 29th. The biotechnology company reported ($2.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.83). Pulmatrix had a negative return on equity of 32.97% and a negative net margin of 390.23%. Research analysts expect that Pulmatrix will post -5.68 earnings per share for the current year.
About Pulmatrix (Get Rating)
Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
- Get a free copy of the StockNews.com research report on Pulmatrix (PULM)
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
- Wolverine Worldwide Is Ready To Rebound
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.